shutterstock_504234469_garrykillian
GarryKillian / Shutterstock.com
22 March 2021Big PharmaSarah Kostiuk-Smith

Got a patent, now where to validate?

Securing a European patent covering your drug candidate, or a potentially valuable formulation or dosage regimen, is certainly cause for celebration. However, it necessitates a big decision: where do you validate your new patent? That is, which of the 38 European Patent Convention (EPC) countries spanning from Iceland to Turkey will you select for the patent to be effective and enforceable?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
2 January 2019   Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.

More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
2 January 2019   Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.

More on this story

Americas
19 May 2017   AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira.
Americas
2 January 2019   Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.